To establish whether RICTOR/mTORC2 downregulation affects the responses of melanoma cells to BRAFi-based targeted therapy, we stably silenced RICTOR in three BRAF-mutated human melanoma cell lines (M14, A375 and SK-MEL-28) via lentiviral delivery of two separate RICTOR-targeted shRNAs (shR1, shR2), and compared their effects with those of a scramble control shRNA (shC). The gene discussed is BRAF; the disease is melanoma.